Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • HLA Today
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • MDS
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
      • Myeloproliferative Neoplasms
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • Order Kits
    • HLA Typing for Family Members
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Medical Education & Research
    • Browse News
    • Browse Research
      • Mismatched donor sources may fill an unmet need for patients without fully matched family or unrelated donors
      • Hematopoietic cell donor type may not impact quality of life post-transplant
      • Novel three-drug combination improves GVHD-free and relapse-free survival and relapse after allogeneic transplant
      • Long-term risks of hematological malignancy, autoimmune or thrombotic events do not differ in bone marrow and filgrastim-mobilized PBSC donors
      • Socioeconomic status but not race and ethnicity is likely associated with chronic GVHD outcomes after allogeneic HCT
      • Linkage across research databases may provide a more complete understanding of HCT patient outcomes
      • Race and ethnicity matching may not impact umbilical cord blood transplant patient outcomes
    • Education Catalog
      • State of the Science in Ensuring a Donor for All
      • Predicting and Addressing Relapse After HCT
      • After the Results Quality of Life Pre- and Post-Transplant
    • Materials Catalog
    • HCT Presentation Slides
    • About Our Research
    • Transplant Enews
  • Resources
    • Patient Resources
    • Financial Resources
    • Obstetrician Resources
    • Technique Videos
    • Umbilical Cord Blood Collection Training for Public Donation
    • Local Provider Partnership Program
  • Browse News
  • Browse Research
  • Education Catalog
  • Materials Catalog
  • HCT Presentation Slides
  • About Our Research
  • Transplant Enews

  • Medical Education & Research
  • Browse Research
  • Email
  • Print This Page

Choose a Topic

  • All Topics
  • Patient Eligibility
  • AML
  • Unrelated Donor HCT
  • Post-Transplant
  • CIBMTR Publications
  • GVHD
  • ALL
  • Lymphomas and CLL
  • Preparative Regimens
  • Pediatric HCT
  • Older Patient HCT
  • MDS
  • Non-Malignant Disorders
  • BMT CTN Publications
  • Cord Blood
  • Multiple Myeloma
  • Sickle Cell Disease
  • HLA Matching
  • ASH 2015
  • ASH 2017
  • ASH 2016
  • ASH 2020
  • CML
  • ASH 2018
  • Neuroblastoma
- Collapse

Subscribe to E-News

Receive new research summaries monthly.

Subscribe Now

Related Resources

Browse News
CIBMTR Research
Education Activities
Back to Top

Recent Research

Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.

  • No Benefit of Additional Treatment After Auto-HCT for Myeloma with Lenalidomide Maintenance

    December 2016
    Stadtmauer E, et al. ASH abstract oral presentation, December 2016 – The addition of consolidation therapy or a second autologous transplant is not superior to a single autologous transplant followed by lenalidomide maintenance in the upfront treatment of multiple myeloma, according to research presented at the Late-Breaking Abstracts session at ASH.

    Read More

  • High-Risk Patients with AML Undergoing Early HCT Have Improved Outcomes

    December 2016
    Pagel JM, et al. ASH abstract oral presentation, December 2016 – In newly diagnosed adults with acute myeloid leukemia (AML), early identification of high-risk cytogenetics and HLA testing with an organized effort to identify a suitable allogeneic hematopoietic cell transplant (HCT) donor can lead to a higher transplant rate and better transplant outcomes, according to research presented at ASH.

    Read More

  • Adults with ALL Experience No Benefit of Consolidation Chemotherapy Prior to HCT

    December 2016
    Bejanyan N, et al. ASH abstract oral presentation, December 2016 – Consolidation chemotherapy does not benefit adults with acute lymphoblastic leukemia (ALL) who have a readily available donor and who undergo myeloablative allogeneic hematopoietic cell transplantation (HCT) in first complete remission (CR1), according to research presented at ASH.

    Read More

  • Adding Sirolimus to Standard GVHD Prophylaxis Significantly Reduces Acute GVHD

    December 2016
    Sandmaier B, et al. ASH abstract oral presentation, December 2016 – Adding sirolimus to a standard graft-versus-host disease (GVHD) prophylaxis of mycophenolate mofetil (MMF) and cyclosporine (CSP) can significantly reduce the risks of grades II-IV and III-IV acute GVHD and non-relapse mortality (NRM), according to results of a phase 3 multi-center randomized trial presented at ASH.

    Read More

  • Comparable HCT Survival and Incidence of Toxicity for Patients ≥60 Years

    December 2016
    Shah GL, et al. ASH abstract oral presentation, December 2016 – Survival of patients ≥60 years undergoing ex vivo CD34+ selected reduced-intensity hematopoietic cell transplantation (HCT) was comparable to that of patients <60 years, according to research presented at ASH.

    Read More

  • Somatic Mutations Can Improve Transplant Prognostics in MDS

    December 2016
    Rossi M, et al. ASH abstract oral presentation, December 2016 – In patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) evolving from MDS (MDS/AML), somatic mutation information can be combined with revised International Prognostic Scoring System (IPSS-R) risk categorizations to predict post-transplant relapse risk, according to research presented at ASH.

    Read More

  • Email
  • Print This Page

Transplant Indications and Outcomes

  • HLA Today
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • Order Kits
  • HLA Typing for Family Members

Transplant Therapy and Donor Matching

  • Cell Sources
  • HLA Typing and Matching
  • Donor or Cord Blood Search Process
  • Jason Carter Clinical Trials Program

Resources

  • Patient Resources
  • Financial Resources
  • Obstetrician Resources
  • Technique Videos
  • Umbilical Cord Blood Collection Training for Public Donation
  • Local Provider Partnership Program

Contact Us

About Us

Our Websites

bethematch.org
BeTheMatch.org Information and support for patients, donors and supporters of our mission.
BeTheMatchBioTherapies.com
BeTheMatchBioTherapies.com Proven solutions for organizations developing and delivering new cellular therapies
CIBMTR.org
CIBMTR.org Transplant research, clinical studies, publications and outcomes data for researchers and clinicians.
National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2023 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright

Choose a Topic

  • All Topics
  • Patient Eligibility
  • AML
  • Unrelated Donor HCT
  • Post-Transplant
  • CIBMTR Publications
  • GVHD
  • ALL
  • Lymphomas and CLL
  • Preparative Regimens
  • Pediatric HCT
  • Older Patient HCT
  • MDS
  • Non-Malignant Disorders
  • BMT CTN Publications
  • Cord Blood
  • Multiple Myeloma
  • Sickle Cell Disease
  • HLA Matching
  • ASH 2015
  • ASH 2017
  • ASH 2016
  • ASH 2020
  • CML
  • ASH 2018
  • Neuroblastoma